Cart 0 items

Comparison

Semaglutide vs Tirzepatide

The two most-searched compounds in metabolic research. The difference is not potency at a shared target, it is the number of receptors involved: one acts at a single incretin receptor, the other at two.

What is the difference between semaglutide and tirzepatide?

Semaglutide is the baseline: it isolates GLP-1 receptor activity, which is what makes it the control in nearly every incretin study. Tirzepatide adds GIP, so it is the compound to use when the research question is specifically what the second receptor contributes. Comparing them is how the GIP contribution gets measured at all.

Side by side

Property Semaglutide Tirzepatide
Receptor targets GLP-1 only GIP and GLP-1
Class Single agonist Dual agonist
Backbone GLP-1 analogue, 31 residues GIP-based sequence engineered for dual affinity
Molar mass 4113.58 g/mol 4813.45 g/mol
Half-life strategy C18 fatty diacid chain, albumin binding C20 fatty diacid chain, albumin binding
Role in research The reference incretin comparator The dual-agonist comparator
Price $55.00 · 5 mg $85.00 · 10 mg

Both compounds

Semaglutide

Semaglutide

5 mg

Long-acting GLP-1 receptor agonist, lyophilised, 5 mg per vial.

CAS
910463-68-2
Storage
Refrigerated

$55.00

In stock

Tirzepatide

Tirzepatide

10 mg

Dual GIP and GLP-1 receptor agonist, 10 mg per vial.

CAS
2023788-19-2
Storage
Refrigerated

$85.00

In stock

Questions

Is tirzepatide just a stronger semaglutide?

No. It acts at an additional receptor. Tirzepatide is a dual GIP and GLP-1 agonist, while semaglutide acts at GLP-1 alone, so the difference is mechanistic rather than a matter of relative strength at one shared target.

What does GIP add?

GIP is the other major incretin hormone. Recruiting it alongside GLP-1 produced larger effects in metabolic models than GLP-1 agonism on its own, and isolating that contribution is the reason the two compounds are studied against each other.

Which came first?

Semaglutide. It established the long-acting GLP-1 analogue as the reference compound, and the dual and triple agonists were developed afterwards against that benchmark.

Other comparisons

All products listed are sold strictly for in-vitro laboratory research and analytical use. They are not drugs, foods, cosmetics or medical devices, and are not intended to diagnose, treat, cure or prevent any disease.